Neosoma
Feb 24, 2023
Neosoma Announced Today a Strategic Partnership with Hackensack Meridian Health for Innovation in Brain Tumor Treatment and Research
Hackensack Meridian Health and Neosoma announced a new strategic partnership to tackle some of the most difficult-to-treat tumors.
The collaboration will include clinical data sharing, clinical research, and strategic investment from the health network to support the Massachusetts-based company’s innovative method of imaging, tracking and collecting data on numerous types of brain tumors including glioblastomas.
“We are committed to investing in research and innovative therapies to live our mission to transform healthcare and give our patients the best possible outcomes,’’ said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. “Partnering with Neosoma Inc. is a great way to continue to develop potential game changing therapies to treat these challenging cancers.”
“We have a terrific partnership with Hackensack Meridian Health already,” said Ken Kolodziej, the CEO and co-founder of Neosoma. “We’re very excited to expand the scope of our collaboration with the shared goal of improving treatment and outcomes for patients with brain cancer.”
The partnership will include HMH physicians using Neosoma’s software in clinical practice, starting with Hackensack Meridian JFK University Medical Center; physician input and feedback for development of future software including neurosurgeons, neuro-oncologists, neuroradiologists, radiation oncologists, and other clinicians; and data sharing for product R&D efforts including collaboration with Anthology Diagnostics for genomics data and capabilities, among other benefits.
Read more about this exciting partnership here.